| Original language | English (US) |
|---|---|
| Pages (from-to) | 412-414 |
| Number of pages | 3 |
| Journal | JACC: Cardiovascular Interventions |
| Volume | 11 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 26 2018 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
First-in-Human Use of a Retention-Enhanced Catheter for Endomyocardial Cell Delivery. / CHART Program.
In: JACC: Cardiovascular Interventions, Vol. 11, No. 4, 26.02.2018, p. 412-414.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - First-in-Human Use of a Retention-Enhanced Catheter for Endomyocardial Cell Delivery
AU - CHART Program
AU - Sherman, Warren
AU - Bartunek, Jozef
AU - Dolatabadi, Dariouch
AU - Sanz-Ruiz, Ricardo
AU - Beleslin, Branko
AU - Wojakowski, Wojtek
AU - Heyndrickx, Guy
AU - Kimpalou, Jose Zefu
AU - Waldman, Scott A.
AU - Laarman, Gerrit J.
AU - Seron, Aymeric
AU - Behfar, Atta
AU - Latere, Jean Pierre
AU - Terzic, Andre
AU - Wijns, William
N1 - Funding Information: Please note: This study was sponsored by Celyad. Dr. Sherman was employed by Celyad during the time CHART-1 was conducted and is now a paid consultant. Dr. Bartunek is a member of an institution that has been a shareholder of Celyad. Dr. Dolatabadi was a study proctor for Celyad and received compensation in that role. Dr. Sanz-Ruiz was a study proctor for Celyad and received compensation in that role. Dr. Beleslin was a study proctor for Celyad and received compensation in that role. Dr. Wojakowski was a study proctor for Celyad and received compensation in that role. Dr. Heyndrickx was a study proctor and is a past consultant to Celyad. Dr. Seron and Mr. Kimpalou were employed by Celyad during the time CHART-1 was conducted. Dr. Waldman was the chair of the data safety and monitoring board for the CHART-1 trial and received compensation from Celyad for that role. Dr. Laarman was a consultant to Celyad and received compensation in that role. Dr. Behfar has received Mayo Clinic–administered research grants from Celyad. Dr. Latere is employed by Celyad. Dr. Terzic has received research grants, administered by the Mayo Clinic, from the Marriott Foundation, the Michael S. and Mary Sue Shannon Family, the Russ and Kathy VanCleve Foundation, the Leducq Fondation, the Florida Heart Research Institute, Celyad, and the National Institutes of Health. The Mayo Clinic has rights to future royalties from Celyad. Dr. Wijns has received institutional grants and support for research from Celyad. Cardiovascular Research Center Aalst was a cofounder of Cardio3Biosciences, now Celyad. Dr. Wijns is a shareholder and nonexecutive board member of Argonauts and Genae and a past board member and past shareholder of Cardio3Biosciences. Cardiovascular Research Center Aalst has received research grants on behalf of Dr. Wijns from several medical device companies (outside the submitted work). Drs. Sherman and Bartunek contributed equally to this work.
PY - 2018/2/26
Y1 - 2018/2/26
UR - http://www.scopus.com/inward/record.url?scp=85042447242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042447242&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2017.10.036
DO - 10.1016/j.jcin.2017.10.036
M3 - Letter
C2 - 29471956
AN - SCOPUS:85042447242
VL - 11
SP - 412
EP - 414
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
SN - 1936-8798
IS - 4
ER -